PD-L1 expression in malignant salivary gland tumors.
PD-L1 expression in malignant salivary gland tumors.
复制标题
PD-L1在涎腺恶性肿瘤中的表达
DOI：
10.1186/s12885-018-4069-3
复制
发表时间：
2018-02-06
期刊：
影响因子：
3.8
通讯作者：
Ueyama Y
中科院分区：
文献类型：
--
作者：
Harada K;Ferdous T;Ueyama Y
程序性死亡 1 配体 1 (PD-L1) 是一种重要的癌症生物标志物，可以抑制免疫系统，据报道，其高表达通常与某些癌症中肿瘤侵袭性的增加有关。在这里，我们检查并评估了恶性唾液腺肿瘤患者的 PD-L1 表达。此外，还研究了PD-L1免疫定位与唾液腺恶性肿瘤的临床病理特征以及预后之间的关系。我们通过免疫组织化学染色检测了 47 例唾液腺恶性肿瘤患者的 PD-L1 表达。 PD-L1阳性定义为肿瘤细胞膜中≥5%，并根据肿瘤浸润单核细胞(TIMC)中的三类(0% = 0、< 5% = 1、≥5% = 2)进行评估。 Fisher精确检验用于比较PD-L1表达与临床病理特征，Kaplan-Meier法用于估计PD-L1阳性的OS分布。 51.1%的唾液腺恶性肿瘤组织中检测到PD-L1表达。未观察到肿瘤中 PD-L1 免疫定位与患者性别或年龄之间存在关联。然而，肿瘤细胞膜的PD-L1免疫检测与分期、术后复发或转移以及患者预后显着相关。另一方面，肿瘤浸润单核细胞 (TIMC) 的 PD-L1 免疫检测与术后复发或转移以及患者预后显着相关。肿瘤细胞膜和 TIMC 中的 PD-L1 阳性与较短的总生存期 (OS) 相关（分别为 p = 0.002 和 p = 0.016）。这些发现表明，PD-L1 阳性肿瘤或 TIMC 患者在恶性唾液腺肿瘤中的临床结果似乎较差。
Programmed death-1 ligand-1 (PD-L1) an important cancer biomarker that can suppress the immune system and its high expression is often reported to be related with increased tumor aggressiveness in some cancers. Here, we examined and evaluated PD-L1 expression in patients with malignant salivary gland tumor. Moreover, the relationship between PD-L1 immunolocalization and clinical pathological features, as well as the prognosis of malignant salivary gland tumors was investigated. We examined PD-L1expression in 47 patients with malignant salivary gland tumor by immunohistochemical staining. PD-L1 positivity was defined as ≥5% in tumor cell membrane and evaluated according to three categories (0% = 0, < 5% = 1, ≥5% = 2) in tumor-infiltrating mononuclear cells (TIMCs). Fisher’s exact test was used to compare between PD-L1 expression and clinico-pathological features, and Kaplan–Meier method was used to estimate the distribution of OS by PD-L1 positivity. PD-L1 expression was detected in 51.1% of malignant salivary gland tumor tissues. No association was observed between PD-L1 immunolocalization in tumor and patient gender, or age. However, PD-L1 immunodetection of tumor cell membranes was significantly associated to stage, recurrence or metastasis after surgery, and patient outcome. On the other hand, PD-L1 immunodetection of tumor-infiltrating mononuclear cells (TIMCs) was significantly associated to recurrence or metastasis after surgery, and patient outcome. PD-L1 positivity in both tumor cell membrane and TIMCs was associated with shorter overall survival (OS) (p = 0.002 and p = 0.016, respectively). These findings suggested that patients with PD-L1 positive tumors or TIMCs appear to have poor clinical outcomes in malignant salivary gland tumors.
登录
查看更多内容
DOI：
10.1073/pnas.0406351101
发表时间：
2004-12-07
影响因子：
11.1
作者：
Thompson, RH;Gillettt, MD;Kwon, ED
通讯作者：
Kwon, ED
影响因子：
11.5
作者：
Ohigashi, Y;Sho, M;Nakajima, Y
通讯作者：
Nakajima, Y
DOI：
10.1084/jem.193.7.839
发表时间：
2001-04-02
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Tseng SY;Otsuji M;Gorski K;Huang X;Slansky JE;Pai SI;Shalabi A;Shin T;Pardoll DM;Tsuchiya H
通讯作者：
Tsuchiya H
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM
影响因子：
3.8
作者：
Speight, PM;Barrett, AW
通讯作者：
Barrett, AW